TickerHumSide-by-side comparison
Biogen vs Johnson & Johnson
As of Nov 11, 2026, P/E is 109.7x for Biogen vs 42.6x for Johnson & Johnson; P/S is 3.6x for Biogen vs 6.8x for Johnson & Johnson; revenue growth is 2.3% for Biogen vs 7.8% for Johnson & Johnson; net margin is 3.4% for Biogen vs 16.2% for Johnson & Johnson.
What stands out
- Johnson & Johnson is cheaper on earnings: 42.6x P/E vs 109.7x for Biogen.
Key metrics
| Metric | BIIB | JNJ |
|---|---|---|
| Price | $253.40 | $280.41 |
| Market cap | $37.46B | $675.03B |
| P/E | 109.7x (#2) | 42.6x (#1) |
| P/S | 3.6x (#1) | 6.8x (#2) |
| Revenue growth | 2.3% (#2) | 7.8% (#1) |
| Operating margin | — | — |
| Net margin | 3.4% (#2) | 16.2% (#1) |
| Debt / equity | 0.39 (#1) | 0.44 (#2) |
| 1-year return | — | — |
| Research score | 53/100 (#2) | 60/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Biogen Inc. (BIIB) — Drug Manufacturers—General
- Johnson & Johnson (JNJ) — Drug Manufacturers—General